Ziltivekimab lowers inflammation but fails Phase 3 cardiovascular outcomes test
Ziltivekimab lowered IL-6 activity and hsCRP but failed to reduce major cardiovascular events in Novo Nordisk’s 6,300-patient ZEUS trial.
Pharma & Biotech
Pharma & Biotech
How Novo Nordisk may be lowering one of the biggest operational barriers in GLP-1 distribution
Read how Novo Nordisk may be reducing one of the biggest GLP-1 delivery barriers in Europe and what it could mean for Wegovy’s market expansion.
Pharma & Biotech
Novo Nordisk’s CagriSema misses non-inferiority against tirzepatide: Why a 23% weight loss still reshapes the obesity pipeline
Novo Nordisk A/S disclosed headline Phase 3 data from the REDEFINE 4 trial showing that CagriSema, its fixed-dose combination of cagrilintide and semaglutide, achieved 23 percent weight loss over 84 weeks in people with obesity but failed to meet the primary endpoint of non-inferiority versus tirzepatide. The open-label head-to-head study compared once-weekly CagriSema 2.4 mg/2.4
Pharma & Biotech
Novo Nordisk secures EU nod for higher Wegovy dose amid intensifying GLP-1 competition
EU approves 7.2 mg Wegovy for obesity. Explore what this means for efficacy, competition and reimbursement across Europe.